STROKE PREVENTION

被引:116
作者
GORELICK, PB
机构
[1] RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT NEUROL SCI, CEREBROVASC DIS SECT, CHICAGO, IL 60612 USA
[2] RUSH PRESBYTERIAN ST LUKES MED CTR, NEUROEPIDEMIOL UNIT, CHICAGO, IL 60612 USA
[3] UNIV ILLINOIS, SCH PUBL HLTH, EPIDEMIOL & BIOMETRY PROGRAM, CHICAGO, IL USA
关键词
D O I
10.1001/archneur.1995.00540280029015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke is ideally suited for prevention. It has a high prevalence, burden of illness, and economic cost, and safe and effective prevention measures. The estimated $30 billion that is being spent for stroke each year in the United States should not come as a surprise given the approximately 3 million stroke survivors and 400 000 to 500 000 new or recurrent stroke cases annually. Stroke remains the third leading cause of death among adults and has been targeted for cost containment by managed tare health systems and other insurers. The US Public Health Service in conjunction with the National Health Promotion and Disease Prevention Objectives has set a goal to reduce stroke deaths to 20 per 100 000 by the year 2000. This goal could be attained as the estimate of ''preventable'' strokes could be as high as 80%. In this article, I will review the status of stroke risk factors, prevention approaches to reduce stroke, clinical trial data from primary and secondary stroke prevention studies, and future directions in stroke prevention.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 126 条
  • [1] RISK OF STROKE IN MALE CIGARETTE SMOKERS
    ABBOTT, RD
    YIN, Y
    REED, DM
    YANO, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (12) : 717 - 720
  • [2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [3] ANDERSON DC, 1990, STROKE, V21, P12
  • [4] PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK
    ANDERSON, DC
    ASINGER, RW
    NEWBURG, SM
    FARMER, CC
    WANG, K
    BUNDLIE, SR
    KOLLER, RL
    JAGIELLA, WM
    KREHER, S
    JORGENSEN, CR
    SHARKEY, SW
    FLAKER, GC
    WEBEL, R
    NOLTE, B
    STEVENSON, P
    BYER, J
    WRIGHT, W
    CHESEBRO, JH
    WIEBERS, DO
    HOLLAND, AE
    MILLER, DM
    BARDSLEY, WT
    LITIN, SC
    MEISSNER, I
    ZERBE, DM
    MCANULTY, JH
    MARCHANT, C
    COULL, BM
    FELDMAN, G
    HAYWARD, A
    GANDARA, E
    MACMILLAN, K
    BLANK, N
    LEONARD, AD
    KANTER, MC
    ISENSEE, LM
    QUIROGA, ES
    PRESTI, CH
    TEGELER, CH
    LOGAN, WR
    HAMILTON, WP
    GREEN, BJ
    BACON, RS
    REDD, RM
    CADELL, DJ
    GOMEZ, CR
    JANOSIK, DL
    LABOVITZ, AJ
    KELLEY, RE
    CHAHINE, R
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) : 1 - 5
  • [5] ANDERSON DC, 1992, ANN INTERN MED, V116, P6
  • [6] [Anonymous], 1989, Stroke, V20, P844
  • [7] [Anonymous], 1990, Stroke, V21, P1122
  • [8] [Anonymous], 1985, Stroke, V16, P406
  • [9] [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409
  • [10] [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316